Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASLNNASDAQ:CWBRNASDAQ:OCEANASDAQ:PBLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/ACWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AOCEAOcean Biomedical$0.01+2.7%$0.00$0.01▼$1.75$268K1.3117.08 million shs2.09 million shsPBLAPanbela Therapeutics$0.24-3.4%$0.30$0.23▼$0.48$1.15M1.3418,792 shs16,699 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%-83.38%CWBRCohBar0.00%0.00%0.00%0.00%-46.06%OCEAOcean Biomedical-3.85%-16.67%-63.41%-94.05%-99.52%PBLAPanbela Therapeutics-3.38%-5.16%-30.91%-43.29%-47.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AOCEAOcean Biomedical0.4964 of 5 stars0.05.00.00.00.01.70.0PBLAPanbela TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals 0.00N/AN/AN/ACWBRCohBar 0.00N/AN/AN/AOCEAOcean Biomedical 0.00N/AN/AN/APBLAPanbela Therapeutics 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09CWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AOCEAOcean BiomedicalN/AN/AN/AN/A($2.62) per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$21.92N/A∞N/AN/A-8,454.87%-121.60%N/ACWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AOCEAOcean Biomedical-$114.47M-$0.94N/A∞N/AN/AN/A-931.55%N/APBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%5/26/2025 (Estimated)Latest OCEA, ASLN, PBLA, and CWBR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2025Q4 2024OCEAOcean BiomedicalN/A$0.02N/A$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AOCEAOcean BiomedicalN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.051.05CWBRCohBarN/AN/AN/AOCEAOcean BiomedicalN/A0.030.03PBLAPanbela TherapeuticsN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%CWBRCohBar2.47%OCEAOcean Biomedical24.55%PBLAPanbela Therapeutics4.37%Insider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%CWBRCohBar6.51%OCEAOcean Biomedical73.50%PBLAPanbela Therapeutics0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals302.04 million1.95 millionOptionableCWBRCohBar102.91 millionN/ANot OptionableOCEAOcean BiomedicalN/A34.87 million9.24 millionOptionablePBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableOCEA, ASLN, PBLA, and CWBR HeadlinesRecent News About These CompaniesPanbela Therapeutics (NASDAQ:PBLA) Trading Up 2.3% - Here's WhyMay 23 at 2:33 AM | americanbankingnews.comPanbela Therapeutics Announces Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comPanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.dePanbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...November 15, 2024 | finance.yahoo.comPanbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 14, 2024 | globenewswire.comPanbela Therapeutics (OTC:PBLA) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comHorace Mann Educators (NYSE:HMN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPanbela Therapeutics (OTC:PBLA) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | insidermonkey.comPanbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q2 2024 Financial ResultsAugust 13, 2024 | globenewswire.comIs Panbela Therapeutics Inc (PBLA) Stock a Good Investment?August 3, 2024 | aaii.comPanbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024July 30, 2024 | globenewswire.comPanbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial ModificationJune 24, 2024 | globenewswire.comPanbela Therapeutics Inc. (PBLA) Insider ActivityMay 25, 2024 | nasdaq.comHC Wainwright & Co. Downgrades Panbela Therapeutics (PBLA)May 17, 2024 | msn.comQ1 2024 Panbela Therapeutics Inc Earnings CallMay 16, 2024 | uk.finance.yahoo.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call TranscriptMay 16, 2024 | msn.comPanbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 16, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBP Buyout Buzz Puts Spotlight on Transocean’s Comeback PotentialBy Gabriel Osorio-Mazilli | May 12, 2025View BP Buyout Buzz Puts Spotlight on Transocean’s Comeback PotentialWhy Energy Stocks Like Exxon and Hess Are Back in FocusBy Gabriel Osorio-Mazilli | May 4, 2025View Why Energy Stocks Like Exxon and Hess Are Back in FocusOCEA, ASLN, PBLA, and CWBR Company DescriptionsASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 05/23/2025ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.CohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Ocean Biomedical NASDAQ:OCEAAesther Healthcare Acquisition Corp. entered into definitive merger agreement with Ocean Biomedical, Inc.Panbela Therapeutics NASDAQ:PBLA$0.24 -0.01 (-3.38%) As of 05/23/2025 02:10 PM EasternPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
